Cite
Synergistic Effects of the RAR alpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation.
MLA
Fleischmann, Maximilian, et al. “Synergistic Effects of the RAR Alpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation.” Cancers, vol. 16, no. 7, Apr. 2024, p. 1311. EBSCOhost, https://doi.org/10.3390/cancers16071311.
APA
Fleischmann, M., Bechwar, J., Voigtländer, D., Fischer, M., Schnetzke, U., Hochhaus, A., & Scholl, S. (2024). Synergistic Effects of the RAR alpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation. Cancers, 16(7), 1311. https://doi.org/10.3390/cancers16071311
Chicago
Fleischmann, Maximilian, Julia Bechwar, Diana Voigtländer, Mike Fischer, Ulf Schnetzke, Andreas Hochhaus, and Sebastian Scholl. 2024. “Synergistic Effects of the RAR Alpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation.” Cancers 16 (7): 1311. doi:10.3390/cancers16071311.